# Bioavailability of KBP-5074 Tablet vs Capsule Formulations

> **NCT03340753** · PHASE1 · COMPLETED · sponsor: **KBP Biosciences** · enrollment: 20 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** KBP-5074 Capsule
- **DRUG:** KBP-5074 Tablet

## Key facts

- **NCT ID:** NCT03340753
- **Lead sponsor:** KBP Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-26
- **Primary completion:** 2017-11-22
- **Final completion:** 2017-12-19
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03340753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03340753, "Bioavailability of KBP-5074 Tablet vs Capsule Formulations". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03340753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*